In patient-derived low-passage xenografts, α2β1-integrin was expressed by 0.2–0.4% of bulk tumor cells and 2.8–4.3% of ALDH+ cells, a 12–37 fold increase by CSCs (Fig 3b). Here, LDHA is linked to neoplasm.